Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Sep 10, 2026, 11:02 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–13 of 13 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Conditions
Osteoarthritis (OA) of the Knee
Interventions
Periarticular Injection, Adductor Canal Block, Bupivacaine-Meloxicam
Drug
Lead sponsor
Henry Ford Health System
Other
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Grosse Pointe Farms, Michigan
Conditions
Total Knee Arthroplasty
Interventions
HTX-011, ropivacaine , epinephrine , ketorolac diluted in sodium chloride
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
209 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Rochester, Minnesota
Completed Phase 3 Interventional Results available

Study of Post-Herniorrhaphy Non-opioid MMA Regimens

NCT03907176
Conditions
Analgesia
Interventions
HTX-011, Luer lock applicator, Ibuprofen, Acetaminophen
Drug · Device
Lead sponsor
Heron Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
209 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
30
States / cities
Anaheim, California • La Mesa, California • Orange, California + 22 more
Completed Phase 2 Interventional Results available

HTX-011 for Post-bunionectomy Analgesia

NCT02471898
Conditions
Analgesia
Interventions
HTX-011, Placebo
Drug
Lead sponsor
Heron Therapeutics
Industry
Eligibility
18 Years to 65 Years
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015
U.S. locations
1
States / cities
Pasadena, California
Conditions
Analgesia
Interventions
Bupivacaine Hydrochloride, HTX-011, Luer lock applicator, Ibuprofen, Acetaminophen
Drug · Device
Lead sponsor
Heron Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
7
States / cities
Little Rock, Arkansas • Sarasota, Florida • Tulsa, Oklahoma + 4 more
Conditions
Post Operative Pain
Interventions
Zynrelef, Exparel
Drug
Lead sponsor
Texas Tech University Health Sciences Center
Other
Eligibility
18 Years to 65 Years
Enrollment
130 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2028
U.S. locations
1
States / cities
Lubbock, Texas
Conditions
Postoperative Pain, Total Shoulder Arthroplasty, Multimodal Analgesia
Interventions
HTX-011, Bupivacaine Hydrochloride, Ibuprofen, Acetaminophen, Luer lock applicator
Drug · Device
Lead sponsor
Heron Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
5
States / cities
Little Rock, Arkansas • Jenks, Oklahoma • Bellaire, Texas + 2 more
Conditions
Post Operative Pain, Osteoarthritis, Knee
Interventions
Bupivacaine-Meloxicam 400 Mg-12 Mg/14 mL Injectable Solution, Extended Release
Drug
Lead sponsor
Baptist Health South Florida
Other
Eligibility
35 Years to 70 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Miami, Florida
Conditions
Analgesia
Interventions
HTX-011, Bupivacaine Hydrochloride, Ibuprofen, Acetaminophen, Luer lock applicator
Drug · Device
Lead sponsor
Heron Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
2
States / cities
Bellaire, Texas • San Antonio, Texas
Not listed Phase 3 Interventional Accepts healthy volunteers

Pain Relief After PrimaryTKA

NCT05751421
Conditions
Pain, Postoperative
Interventions
Zynrelef (Bupivacaine 60 MG / Meloxicam 1.8 MG) Per 2.3 ML Extended Release Solution, Bupivacaine HCl 0.5% Injectable Solution, primary total knee replacement
Drug · Procedure
Lead sponsor
Rothman Institute Orthopaedics
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Not yet recruiting Phase 4 Interventional Accepts healthy volunteers

Zynrelef Versus Adductor Canal Block

NCT07216586
Conditions
Knee Osteoarthritis, Arthritis Knee
Interventions
ZYNRELEF 400Mg-12Mg Extended-Release Solution, Ultrasound-Guided Adductor Canal Block, Ropivacaine 0.5% Injectable Solution
Drug · Procedure
Lead sponsor
University of Miami
Other
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2027 – 2028
U.S. locations
1
States / cities
Miami, Florida
Conditions
Post Operative Pain, Acute, Bariatric Surgery Candidate, Postoperative Pain
Interventions
ZYNRELEF 200Mg-6Mg Extended-Release Solution
Drug
Lead sponsor
Dr. Yannis Raftopoulos
Other
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Holyoke, Massachusetts
Conditions
Total Shoulder Arthroplasty, Pain Management
Interventions
Zynrelef, Bupivacaine
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
86 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
St Louis, Missouri